Clinical Trial · NCT05533086

PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer

Overview

Clinical trials have shown efficacy of PD1/PD-L1 checkpoint inhibitors in multiple solid tumors, including NSCLC. Whole body information with regard to target presence, drug kinetics and dynamics, as well as binding of PD-L1 targeting agents to the immune system cells is lacking.Molecular imaging of PD-L1 could lead to new insights on heterogeneity of PD-L1 expression in metastatic lesions and be of help in the prediction of response to PD1/PD-L1 inhibitors in a noninvasive manner.

Sponsor

Tongji Hospital

Contacts

ZHU XIAOHUA, DR (PRINCIPAL_INVESTIGATOR)

ZHU XIAOHUA, DR (CONTACT)

evazhu@vip.sina.com

13971513770

ClinicalTrials.gov

NCT05533086

Drug / Compound

BMS986192

Isotope(s):

Target(s):

PD-L1

Ligand Class: Small Proteins and Antibody Fragments

Chelator: NODAGA

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

\- (1) Female patients during pregnancy and lactation. (2) Patients with psychiatric disease, severe hepatic and renal insufficiency. (3) Patients who refuse anti-PD-1/PD-L1 therapy. (4) Patients who are claustrophobic or unable to undergo PET/CT examination. (5) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, except anti-CTLA4 antibody.(6) Those who, in the opinion of the investigator, are otherwise unsuitable for clinical trials.